GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Selling and Marketing Expense

Telix Pharmaceuticals (Telix Pharmaceuticals) Selling and Marketing Expense : $36.7 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Telix Pharmaceuticals's Selling and Marketing Expense for the six months ended in Dec. 2023 was $32.2 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $36.7 Mil.

Telix Pharmaceuticals Selling and Marketing Expense Historical Data

The historical data trend for Telix Pharmaceuticals's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Selling and Marketing Expense Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only 0.22 0.91 4.21 10.92 36.73

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.51 7.28 3.93 4.54 32.20

Telix Pharmaceuticals Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $36.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Selling and Marketing Expense
Comparable Companies
ASX:NEU ASX:CUV ASX:IMM ASX:IMU ASX:MSB ASX:CU6 ASX:PYC ASX:OPT ASX:BOT ASX:PAR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
TLX:Australia
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Website
https://www.telixpharma.com
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.